Research analysts covering Aspira Women's Health.
Recent press releases and 8-K filings for AWHL.
Aspira Women's Health Inc. secures $1.05 million subordinated business loan
AWHL
Debt Issuance
- Aspira Women's Health Inc. entered into a Subordinated Business Loan and Security Agreement on January 30, 2026, with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent, for a secured term loan.
- The proceeds from this loan will be used for general corporate purposes.
- The Company granted a continuing security interest in substantially all of its and its co-borrowers' personal property, including intellectual property, and the note is expressly subordinated in right of payment to all Senior Indebtedness.
- The agreement includes customary affirmative and negative covenants, with certain financial covenant requirements waived.
| Metric | Q4 2025 (as of Jan 30, 2026) |
|---|---|
| Principal Amount of Loan ($USD) | $1,050,000 |
| Interest Charges ($USD) | $441,000 |
| Total Repayment Amount ($USD) | $1,491,000 |
| Administrative Agent Fee ($USD) | $50,000 |
| Maturity Date | August 26, 2026 |
8 days ago
Aspira Women's Health Inc. Publishes Investor Presentation Detailing Strategy and Financials
AWHL
Earnings
New Projects/Investments
Guidance Update
- Aspira Women's Health Inc. (AWHL) published an investor presentation on December 29, 2025, outlining its strategy and financial performance.
- The company's product pipeline includes commercially available OvaSuite tests, with ~240,000 tests ordered since launch through September 2025, and new AI-powered tests under development for endometriosis (ENDOinform) and next-generation ovarian cancer assessment.
- As of September 30, 2025, the company reported $3.8 million in cash and cash equivalents and $1.1 million in long-term debt.
- Year-to-date financial performance as of Q3 2025 showed a 2% increase in product revenue, a 570 basis point improvement in gross margin to 64.1%, a 41.9% reduction in operating expenses, and a 19.6% reduction in net loss compared to the prior year.
- AWHL is implementing a new commercial strategy focused on improving profitability by targeting high-reimbursing markets, exiting unprofitable ones, and revamping its compensation plan starting Q3 2025.
Dec 31, 2025, 12:00 PM
Aspira Women's Health Inc. enters into $10.0 million stock purchase agreement with Lincoln Park Capital Fund, LLC
AWHL
- Aspira Women's Health Inc. (AWHL) entered into a Purchase Agreement and a Registration Rights Agreement with Lincoln Park Capital Fund, LLC on December 23, 2025.
- Under the Purchase Agreement, Lincoln Park committed to purchase up to $10.0 million of AWHL's common stock at the Company's discretion over a period of up to 24 months.
- As consideration for the commitment, AWHL issued 824,493 shares of common stock to Lincoln Park, representing 3.0% of the aggregate commitment.
- The purchase price for regular purchases will be 95% of the lower of the lowest sale price of the common stock on the purchase date or the average of the three lowest closing sale prices during the ten business days prior to the purchase date.
- AWHL has the right to terminate the Purchase Agreement at any time with one business day's notice, without cost or penalty.
Dec 23, 2025, 9:34 PM
Aspira Women's Health Inc. Announces Q3 2025 Financial Results and Strategic Update
AWHL
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Aspira Women's Health Inc. reported $2.3 million in total product revenues for the third quarter of 2025, which was relatively flat compared to the prior year, while the average unit price per test (AUP) grew by 7.0% year-over-year.
- For the nine months ended September 30, 2025, the company generated approximately $7.0 million in revenue, achieved a 64.1% gross margin, and reduced total operating expenses by 34.0% to $11.1 million compared to the same period in 2024.
- Cash used in operations for the nine months ended September 30, 2025, decreased significantly by 54.5% to $5.0 million compared to $11.1 million in the prior year period.
- The company is undergoing a strategic transformation, focusing on profitable revenue growth and emphasizing relationships with large healthcare systems, which led to a 167% increase in sales per full-time equivalent salesperson (FTE) in Q3 2025 compared to Q3 2024.
Nov 14, 2025, 1:54 PM
AWHL Amends Securities Purchase Agreement and Warrant Terms
AWHL
Board Change
Convertible Preferred Issuance
- Aspira Women's Health Inc. (AWHL) entered into an amendment to its Securities Purchase Agreement on September 19, 2025, which requires the company to file a registration statement on Form S-1 by September 30, 2025, to register the shares of Common Stock and shares underlying the Warrants.
- The amendment grants the purchasers, as a group, the right to appoint an aggregate of three directors to the Company's Board of Directors under specified conditions.
- The Amended and Restated Series A Common Stock Warrants now feature a fixed exercise price of $0.35 per share, eliminate the cashless exercise option, extend the term from five to six years (until September 19, 2031), and change the initial exercisability to six months after the issuance date (starting March 19, 2026).
Sep 25, 2025, 8:01 PM
Aspira Women's Health Announces Equity Capital Infusion
AWHL
New Projects/Investments
- Aspira Women's Health Inc. announced an equity capital infusion totaling $3.06 million from existing and new investors.
- This infusion comprises a $2.95 million private placement and a $112,500 warrant exercise.
- The private placement, which closed on September 17, 2025, involved the issuance of 6,550,000 additional common shares and 4,912,500 new warrants at a unit price of $0.45.
- The warrants are exercisable at $0.75 per share and have a five-year term.
- Net proceeds from the offering will be used to support ongoing commercial activities, general corporate purposes, and working capital.
Sep 18, 2025, 1:00 PM
Quarterly earnings call transcripts for Aspira Women's Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more